Cagrilintide 10mg Tirzepatide Australia Zepbound beats CagriSema in head to head trial : r Zepbound Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link Clinical trials of subcutaneous tirzepatide, retatrutide, and Download Scientific Diagram CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D)